UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon Beta

NEW YORK CITY, Oct. 28, 2020 (GLOBE NEWSWIRE) — UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon BetaThe Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing for clinical trials of AP-003, its interferon alpha 2b COVID-19 treatment, joined investor portal Proactive to discuss the key differences between the interferon inhalation formula used by BetterLife against that used successfully by Synairgen PLC.The Synairgen trials caused much excitement, strongly demonstrating that treatments using an interferon beta inhalation in COVID-19 patients significantly improved their condition and sped up recovery.  BetterLife is due to start its clinical trials later this fall in Australia for AP-003, BetterLife’s inhaled human interferon alpha 2b, in patients with mild to moderate symptoms of COVID-19.Interferons are a natural part of the body’s innate immune system that are induced upon viral infection, providing the body’s first line of defence against the virus through suppression viral replication and activation of the immune response.  However, interferon production is inhibited by the virus responsible for COVID-19.  While both AP-003 and interferon beta are hypothesized to bypass the COVID-19 induced interferon production blockade, BetterLife believe that their proprietary inhaled alpha 2b (exclusively owned and developed by the Company) could be much more effective against the severity and duration of COVID-19 than interferon beta.In the interview with Proactive, Dr. Doroudian, BetterLife CEO explains why the AP-003 formulation potentially represents a superior mode of treatment over interferon beta due to its proven anti-viral therapeutic.He also discusses:The recent merger between BetterLife and AltumWhy the Company has chosen Australia to kick off its 150 patient clinical trialHow using virtual monitoring technology will help BetterLife with patient recruitmentAbout BDA International, Inc.:
BDA International is an independent global firm offering a wide range of IR and PR related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including BETRF. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and BETRF may do so via the contact information at the bottom of this release.
Disclaimer
The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. BetterLife Pharma is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
Investor Relations Contact:
Dost Mushtaq                                                                      
BDA International    
www.bda-ir.com
dost@bda-ir.com   


CBJ Newsmakers

Recommended
IGNITE Announces Closing of Previously Announced Acquisition of CA$25 Million of IGNITE Shares by Its Chairman and CEODive Technologies Completes Successful Sea Trials with Kraken’s Pressure Tolerant Batteries